Axsome says U.S. FDA asks for no extra data for depression drug, shares surge
Reuters
Published Aug 23, 2021 06:15AM ET
Updated Aug 23, 2021 08:20AM ET
(Reuters) -Axsome Therapeutics Inc said on Monday the U.S. Food and Drug Administration did not ask for additional information on the company's drug to treat depression as the agency continues to review it, sending shares of the drug developer surging 44% before the bell.
The regulator had set an action date of Aug. 22 to decide on the drug, but notified Axsome earlier this month of some deficiencies with its marketing application that could lead to a delay in deciding the fate of the oral pill.
Analysts had expected the FDA to decline Axsome's application, with Truist Securities analyst Joon Lee saying the lack of a "complete response letter" from the FDA was positive as it implied previously identified deficiencies can be remedied.
Shares in Axsome are down 74% this year through Friday's close.
AXS-05 had succeeded in reducing symptoms of major depressive disorder (MDD) in a late-stage trial in December 2019 and also showed benefits for treatment-resistant patients in a mid-stage study in 2020.
Depression affects about 16 million American adults every year, and existing antidepressants including Eli Lilly (NYSE:LLY)'s Prozac and Pfizer Inc (NYSE:PFE)'s Zoloft are designed to increase the availability of a mood-regulating neurotransmitter called serotonin.
But a large number of patients do not respond to those therapies, which could take up to six weeks to show any effect. Companies are developing new drugs that target the treatment-resistant population, which could reach 2.5 million in the United States by 2025, according to SMBC Nikko Securities America analyst David Hoang.
Axsome's AXS-05 targets several neurotransmitters including serotonin and is designed to reduce symptoms of depression in one week.
Rival Sage Therapeutics in June reported data from its late-stage study showing its drug candidate, zuranolone, improved symptoms of depression, but there were concerns about durability.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.